TRIB

Trinity Biotech plc

Price Chart

Latest Quote

$0.58

+0.01 (+1.74%)

Current Price

Previous Close	$0.57
Open	$0.58
Day High	$0.60
Day Low	$0.57
Volume	142,879

Fetched: 2026-06-18T11:39:50

Stock Information

Shares Outstanding	20.25M
Total Debt	$137.98M
Cash Equivalents	$5.14M
Revenue	$43.78M
Net Income	$-37.38M
Sector	Healthcare
Industry	Medical Devices
Market Cap	$11.74M
EPS (TTM)	$-2.00
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$144.39M
Sales	$43.78M
Income	$-37.38M
Book/sh	$-2.93
Cash/sh	$0.25
Employees	287

Financial Ratios

Quick Ratio	0.11
Current Ratio	0.25

Returns & Margins

ROA	-5.72%
Gross Margin	38.57%
Operating Margin	-9.98%
Profit Margin	-85.36%

Ownership

Insider Ownership	16.58%
Institutional Ownership	5.30%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-0.56
PEG	0.30
P/S	0.27
P/B	-0.20

Analyst Data

Recommendation

none

Technical Indicators

SMA20	$0.66
SMA50	$0.65
SMA200	$0.84
RSI	32.35
ATR	0.0657

Shares Float	16.22M
Short Float	1.21%
Short Ratio	2.19
Volatility	0.93
Rel Volume	0.65

Performance History

Week	-15.94%
Month	+1.75%
Quarter	-15.94%
6 Months	-38.30%
YTD	-22.67%
Year	-6.45%
3 Years	-88.95%
5 Years	-96.48%
10 Years	-98.93%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-17	$0.58	143,700
2026-06-16	$0.57	1,494,000
2026-06-15	$0.68	262,100
2026-06-12	$0.65	86,600
2026-06-11	$0.68	174,900
2026-06-10	$0.69	106,300
2026-06-09	$0.66	151,000
2026-06-08	$0.68	114,800
2026-06-05	$0.67	163,600
2026-06-04	$0.68	182,900
2026-06-03	$0.70	134,900
2026-06-02	$0.73	122,100
2026-06-01	$0.72	124,700
2026-05-29	$0.70	87,700
2026-05-28	$0.70	150,700
2026-05-27	$0.68	182,900
2026-05-26	$0.65	364,700
2026-05-22	$0.60	43,700
2026-05-21	$0.63	151,000
2026-05-20	$0.60	146,400
2026-05-19	$0.57	32,000
2026-05-18	$0.57	315,400

About Trinity Biotech plc

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. It has a collaboration agreement with a bioinformatics company to conduct analysis on clinical trial data for EpiCapture, a molecular diagnostics company for developing a non invasive urine based prognostic test for progression to aggressive prostate cancer. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

📰 Latest News

European Equities Traded in the US as American Depositary Receipts Slightly Higher in Tuesday Trading

MT Newswires • 2026-06-16T15:08:44Z

European Equities Traded in the US as American Depositary Receipts Surge in Monday Trading

MT Newswires • 2026-06-15T15:09:48Z

European Equities Traded in the US as American Depositary Receipts Increase in Friday Trading; Rise for Week

MT Newswires • 2026-06-12T15:14:33Z

European Equities Traded in US as ADRs Rise in Thursday Trading

MT Newswires • 2026-06-11T15:09:49Z

European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading

MT Newswires • 2026-06-10T15:07:47Z

European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Rise for Week

MT Newswires • 2026-06-05T15:06:40Z

European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading

MT Newswires • 2026-05-26T15:09:15Z

European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading

MT Newswires • 2026-05-22T15:06:28Z

European Equities Traded in US as ADRs Rise in Wednesday Trading

MT Newswires • 2026-05-20T15:03:01Z

European Equities Traded in the US as American Depositary Receipts Open Week Tracking Higher in Monday Trading

MT Newswires • 2026-05-18T15:11:28Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Reconciled Cost Of Revenue	$26,898,000	$40,114,000	$37,382,000	$45,253,000
Cost Of Revenue	$26,898,000	$40,114,000	$37,382,000	$45,253,000
Total Revenue	$43,785,000	$61,555,000	$56,832,000	$62,521,000
Operating Revenue	$43,785,000	$61,555,000	$56,832,000	$62,521,000
Expenses
Interest Expense	$13,114,000	$11,960,000	$10,148,000	$11,532,000
Total Expenses	$55,201,000	$75,259,000	$72,775,000	$76,034,000
Other Income Expense	$-12,666,000	$-3,894,000	$-12,007,000	$-18,964,000
Net Non Operating Interest Income Expense	$-13,095,000	$-13,132,000	$-8,977,000	$-11,303,000
Total Other Finance Cost	$202,000	$1,172,000	$-1,171,000	$74,000
Interest Expense Non Operating	$13,114,000	$11,960,000	$10,148,000	$11,532,000
Operating Expense	$28,303,000	$35,145,000	$35,393,000	$30,781,000
Other Operating Expenses	-	$1,787,000	$-138,000	$-340,000
Other Non Operating Income Expenses	-	-	$3,000	$3,000
General And Administrative Expense	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-37,376,000	$-31,216,000	$-36,868,000	$-43,586,000
Net Interest Income	$-13,095,000	$-13,132,000	$-8,977,000	$-11,303,000
Interest Income	$221,000	$0	$0	$303,000
Normalized Income	$-26,293,250	$-27,808,750	$-24,877,216	$-24,703,047
Net Income From Continuing And Discontinued Operation	$-37,376,000	$-31,789,000	$-24,018,000	$-41,009,000
Total Operating Income As Reported	$-15,789,000	$-21,165,000	$-27,045,000	$-19,349,000
Net Income Common Stockholders	$-37,376,000	$-31,789,000	$-24,018,000	$-41,009,000
Net Income	$-37,376,000	$-31,789,000	$-24,018,000	$-41,009,000
Net Income Including Noncontrolling Interests	$-37,376,000	$-31,789,000	$-24,018,000	$-41,009,000
Net Income Discontinuous Operations	$0	$-573,000	$12,850,000	$2,577,000
Net Income Continuous Operations	$-37,376,000	$-31,216,000	$-36,868,000	$-43,586,000
Pretax Income	$-37,177,000	$-30,730,000	$-36,927,000	$-43,780,000
Special Income Charges	$-12,666,000	$-3,894,000	$-12,010,000	$-9,289,000
Interest Income Non Operating	$221,000	$0	$0	$303,000
Operating Income	$-11,416,000	$-13,704,000	$-15,943,000	$-13,513,000
Gross Profit	$16,887,000	$21,441,000	$19,450,000	$17,268,000
Per Share
Diluted EPS	-	$-1.77	$-3.20	$-6.08
Basic EPS	-	$-1.77	$-3.20	$-6.08
Other
Tax Effect Of Unusual Items	$-1,583,250	$-486,750	$-19,216	$-84,047
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-8,713,000	$-13,011,000	$-12,992,000	$-10,948,000
Total Unusual Items	$-12,666,000	$-3,894,000	$-12,010,000	$-18,967,000
Total Unusual Items Excluding Goodwill	$-12,666,000	$-3,894,000	$-12,010,000	$-18,967,000
Reconciled Depreciation	$2,684,000	$1,865,000	$1,777,000	$2,333,000
EBITDA (Bullshit earnings)	$-21,379,000	$-16,905,000	$-25,002,000	$-29,915,000
EBIT	$-24,063,000	$-18,770,000	$-26,779,000	$-32,248,000
Diluted NI Availto Com Stockholders	$-37,376,000	$-31,789,000	$-24,018,000	$-41,009,000
Tax Provision	$199,000	$486,000	$-59,000	$-194,000
Other Special Charges	$8,107,000	$-1,695,000	$905,000	$3,450,000
Write Off	$0	$-800,000	$1,500,000	$482,000
Impairment Of Capital Assets	$2,177,000	$2,208,000	$9,605,000	$5,357,000
Restructuring And Mergern Acquisition	$2,382,000	$4,181,000	$0	$0
Research And Development	$3,629,000	$4,543,000	$4,379,000	$4,138,000
Selling General And Administration	$24,674,000	$28,815,000	$31,152,000	$26,983,000
Diluted Average Shares	-	$17,959,674	$8,900,803	$6,746,966
Basic Average Shares	-	$17,959,674	$7,654,970	$6,746,966
Gain On Sale Of Security	-	-	-	$-9,678,000
Gain On Sale Of Business	-	-	-	-
Other Gand A	-	-	-	-

Fetched: 2026-06-16

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$-128,969,000	$-86,524,000	$-40,219,000	$-37,445,000
Total Assets	$105,165,000	$103,290,000	$59,435,000	$92,104,000
Total Non Current Assets	$69,263,000	$62,166,000	$20,394,000	$45,436,000
Other Non Current Assets	$28,000	$28,000	$43,000	$55,000
Non Current Deferred Assets	$3,924,000	$3,553,000	$1,975,000	$4,218,000
Non Current Deferred Taxes Assets	$3,924,000	$3,553,000	$1,975,000	$4,218,000
Financial Assets	$249,000	$166,000	$178,000	$128,000
Investmentin Financial Assets	$2,773,000	$2,455,000	$0	-
Goodwill And Other Intangible Assets	$56,987,000	$51,343,000	$16,270,000	$35,269,000
Other Intangible Assets	$43,021,000	$37,504,000	$16,270,000	$22,732,000
Current Assets	$35,902,000	$41,124,000	$39,041,000	$46,668,000
Prepaid Assets	$1,654,000	$1,979,000	$2,036,000	$1,932,000
Inventory	$18,828,000	$19,374,000	$19,933,000	$22,503,000
Receivables	$10,282,000	$14,604,000	$13,381,000	$15,654,000
Other Receivables	$342,000	$628,000	$1,124,000	$1,158,000
Taxes Receivable	$578,000	$560,000	$1,559,000	$1,877,000
Accounts Receivable	$9,362,000	$13,416,000	$10,698,000	$12,619,000
Allowance For Doubtful Accounts Receivable	$-1,086,000	$-2,286,000	$-2,324,000	$-2,691,000
Gross Accounts Receivable	$10,448,000	$15,702,000	$13,022,000	$15,310,000
Cash Cash Equivalents And Short Term Investments	$5,138,000	$5,167,000	$3,691,000	$6,578,000
Cash And Cash Equivalents	$5,138,000	$5,167,000	$3,691,000	$6,578,000
Cash Financial	$5,138,000	$5,167,000	$3,691,000	$6,578,000
Non Current Accounts Receivable	-	-	$36,000	$84,000
Other Current Assets	-	-	-	$1,000
Cash Equivalents	-	-	-	$0
Debt
Net Debt	$119,417,000	$82,835,000	$51,170,000	$51,679,000
Total Debt	$137,983,000	$100,764,000	$67,427,000	$72,200,000
Long Term Debt And Capital Lease Obligation	$27,170,000	$98,269,000	$65,523,000	$70,314,000
Long Term Debt	$16,330,000	$87,792,000	$54,651,000	$58,047,000
Current Debt And Capital Lease Obligation	$110,813,000	$2,495,000	$1,904,000	$1,886,000
Current Debt	$108,225,000	$210,000	$210,000	$210,000
Other Current Borrowings	$108,015,000	-	-	$210,000
Liabilities
Total Liabilities Net Minority Interest	$177,147,000	$138,471,000	$83,384,000	$94,280,000
Total Non Current Liabilities Net Minority Interest	$35,938,000	$106,376,000	$68,349,000	$76,941,000
Derivative Product Liabilities	$3,320,000	$1,658,000	$526,000	$1,569,000
Non Current Deferred Liabilities	$4,667,000	$4,561,000	$2,300,000	$5,058,000
Non Current Deferred Taxes Liabilities	$4,667,000	$4,561,000	$2,300,000	$5,058,000
Current Liabilities	$141,209,000	$32,095,000	$15,035,000	$17,339,000
Current Deferred Liabilities	$187,000	$197,000	$50,000	$114,000
Current Notes Payable	$210,000	$210,000	$210,000	$210,000
Payables And Accrued Expenses	$29,481,000	$26,837,000	$12,921,000	$15,186,000
Payables	$12,549,000	$13,240,000	$5,369,000	$6,601,000
Other Payable	$413,000	$5,384,000	$800,000	-
Total Tax Payable	$658,000	$1,023,000	$684,000	$396,000
Income Tax Payable	$348,000	$364,000	$279,000	$28,000
Accounts Payable	$11,478,000	$6,833,000	$3,885,000	$6,205,000
Other Non Current Liabilities	-	$1,813,000	-	-
Equity
Common Stock Equity	$-71,982,000	$-35,181,000	$-23,949,000	$-2,176,000
Total Equity Gross Minority Interest	$-71,982,000	$-35,181,000	$-23,949,000	$-2,176,000
Stockholders Equity	$-71,982,000	$-35,181,000	$-23,949,000	$-2,176,000
Other Equity Interest	$6,709,000	$6,709,000	$6,709,000	$6,709,000
Gains Losses Not Affecting Retained Earnings	$-1,440,000	$-5,438,000	$-5,683,000	$-5,689,000
Other Equity Adjustments	$4,337,000	$23,000	$23,000	$86,000
Retained Earnings	$-116,169,000	$-79,117,000	$-48,644,000	$-26,695,000
Other
Treasury Shares Number	$12,555,602	$12,556,000	$12,556,000	$12,556,000
Ordinary Shares Number	$374,206,640	$359,193,482	$153,310,284	$152,430,284
Share Issued	$386,762,242	$371,749,482	$165,866,284	$164,986,284
Tangible Book Value	$-128,969,000	$-86,524,000	$-40,219,000	$-37,445,000
Invested Capital	$52,573,000	$52,821,000	$30,912,000	$56,081,000
Working Capital	$-105,307,000	$9,029,000	$24,006,000	$29,329,000
Capital Lease Obligations	$13,428,000	$12,762,000	$12,566,000	$13,943,000
Total Capitalization	$-55,652,000	$52,611,000	$30,702,000	$55,871,000
Foreign Currency Translation Adjustments	$-5,777,000	$-5,461,000	$-5,706,000	$-5,775,000
Treasury Stock	$24,922,000	$24,922,000	$24,922,000	$24,922,000
Additional Paid In Capital	$63,800,000	$63,397,000	$46,619,000	$46,458,000
Capital Stock	$40,000	$4,190,000	$1,972,000	$1,963,000
Common Stock	$40,000	$4,190,000	$1,972,000	$1,963,000
Long Term Capital Lease Obligation	$10,840,000	$10,477,000	$10,872,000	$12,267,000
Long Term Provisions	$781,000	$75,000	-	-
Current Deferred Revenue	$187,000	$197,000	$50,000	$114,000
Current Capital Lease Obligation	$2,588,000	$2,285,000	$1,694,000	$1,676,000
Pensionand Other Post Retirement Benefit Plans Current	$383,000	$112,000	$110,000	$103,000
Current Provisions	$345,000	$2,454,000	$50,000	$50,000
Current Accrued Expenses	$16,932,000	$13,597,000	$7,552,000	$8,585,000
Investments And Advances	$2,773,000	$2,455,000	$0	-
Goodwill	$13,966,000	$13,839,000	$0	$12,537,000
Net PPE	$5,302,000	$4,621,000	$1,892,000	$5,682,000
Accumulated Depreciation	$-67,523,000	$-66,004,000	$-64,177,000	$-59,924,000
Gross PPE	$72,825,000	$70,625,000	$66,069,000	$65,606,000
Leases	$2,826,000	$2,811,000	$2,760,000	$2,701,000
Machinery Furniture Equipment	$41,438,000	$41,030,000	$39,041,000	$38,223,000
Land And Improvements	$28,561,000	$26,784,000	$24,268,000	$24,682,000
Properties	$0	$0	$0	$0
Finished Goods	$3,605,000	$4,353,000	$5,382,000	$6,461,000
Work In Process	$3,738,000	$4,989,000	$4,498,000	$3,948,000
Raw Materials	$11,485,000	$10,032,000	$10,053,000	$12,094,000

Fetched: 2026-06-16

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-12,152,000	$-14,255,000	$-14,261,000	$-6,898,000
Operating Activities
Operating Cash Flow	$-5,929,000	$-4,191,000	$-11,557,000	$-921,000
Cash Flow From Continuing Operating Activities	$-5,929,000	$-4,191,000	$-11,557,000	$-921,000
Operating Gains Losses	$-1,102,000	$1,010,000	$-12,480,000	$-74,000
Investing Activities
Capital Expenditure	$-6,223,000	$-10,064,000	$-2,704,000	$-5,977,000
Investing Cash Flow	$-6,223,000	$-22,968,000	$24,756,000	$-5,977,000
Cash Flow From Continuing Investing Activities	$-6,223,000	$-22,968,000	$24,756,000	$-5,977,000
Financing Activities
Issuance Of Capital Stock	$547,000	$7,391,000	$0	$25,336,000
Financing Cash Flow	$12,052,000	$28,810,000	$-16,042,000	$-12,322,000
Cash Flow From Continuing Financing Activities	$12,052,000	$28,810,000	$-16,042,000	$-12,322,000
Cash Dividends Paid	$0	$0	$0	$0
Net Common Stock Issuance	$547,000	$7,391,000	$0	$25,336,000
Common Stock Issuance	$547,000	$7,391,000	$0	$25,336,000
Net Other Financing Charges	-	-	$-1,052,000	$-5,743,000
Other
Repayment Of Debt	$-3,187,000	$-2,503,000	$-12,368,000	$-124,014,000
Issuance Of Debt	$15,000,000	$30,176,000	$5,000,000	$100,015,000
End Cash Position	$5,138,000	$5,167,000	$3,691,000	$6,578,000
Beginning Cash Position	$5,167,000	$3,691,000	$6,578,000	$25,910,000
Effect Of Exchange Rate Changes	$71,000	$-175,000	$-44,000	$-112,000
Changes In Cash	$-100,000	$1,651,000	$-2,843,000	$-19,220,000
Interest Paid Cff	$-308,000	$-6,254,000	$-7,622,000	$-7,916,000
Net Issuance Payments Of Debt	$11,813,000	$27,673,000	$-7,368,000	$-23,999,000
Net Long Term Debt Issuance	$11,813,000	$27,673,000	$-7,368,000	$62,731,000
Long Term Debt Payments	$-3,187,000	$-2,503,000	$-12,368,000	$-37,284,000
Long Term Debt Issuance	$15,000,000	$30,176,000	$5,000,000	$100,015,000
Net Investment Purchase And Sale	$0	$0	$-700,000	$0
Purchase Of Investment	$0	$0	$-700,000	$0
Net Business Purchase And Sale	$0	$-12,904,000	$28,160,000	$0
Sale Of Business	$0	$0	$28,160,000	$0
Purchase Of Business	$0	$-12,904,000	$0	$0
Net Intangibles Purchase And Sale	$-6,135,000	$-9,659,000	$-1,901,000	$-4,876,000
Purchase Of Intangibles	$-6,135,000	$-9,659,000	$-1,901,000	$-4,876,000
Net PPE Purchase And Sale	$-88,000	$-405,000	$-803,000	$-1,101,000
Purchase Of PPE	$-88,000	$-405,000	$-803,000	$-1,101,000
Taxes Refund Paid	$-346,000	$1,010,000	$312,000	$-15,000
Interest Received Cfo	$0	$0	$0	$2,000
Change In Working Capital	$7,030,000	$6,188,000	$-402,000	$5,729,000
Change In Other Working Capital	$629,000	$2,113,000	$2,291,000	$7,391,000
Change In Payables And Accrued Expense	$1,391,000	$8,185,000	$-2,769,000	$181,000
Change In Payable	$1,391,000	$8,185,000	$-2,769,000	$181,000
Change In Inventory	$90,000	$-1,742,000	$-971,000	$-877,000
Change In Receivables	$4,920,000	$-2,368,000	$1,047,000	$-966,000
Other Non Cash Items	$20,294,000	$11,270,000	$11,639,000	$24,711,000
Stock Based Compensation	$324,000	$1,316,000	$2,069,000	$1,755,000
Provisionand Write Offof Assets	$187,000	$361,000	$0	$0
Asset Impairment Charge	$2,177,000	$4,092,000	$9,605,000	$5,839,000
Deferred Tax	$199,000	$486,000	$-59,000	$-192,000
Deferred Income Tax	$199,000	$486,000	$-59,000	$-192,000
Depreciation Amortization Depletion	$2,684,000	$1,865,000	$1,777,000	$2,333,000
Depreciation And Amortization	$2,684,000	$1,865,000	$1,777,000	$2,333,000
Amortization Cash Flow	$1,385,000	$1,190,000	$946,000	$923,000
Amortization Of Intangibles	$1,385,000	$1,190,000	$946,000	$923,000
Depreciation	$1,299,000	$675,000	$831,000	$1,410,000
Net Foreign Currency Exchange Gain Loss	$-1,102,000	$1,010,000	$238,000	$-76,000
Gain Loss On Sale Of Business	$0	$0	$-12,718,000	$0
Net Income From Continuing Operations	$-37,376,000	$-31,789,000	$-24,018,000	$-41,009,000
Net Short Term Debt Issuance	-	$0	$0	$-86,730,000
Short Term Debt Payments	-	$0	$0	$-86,730,000
Gain Loss On Sale Of PPE	-	$0	$0	$2,000
Interest Paid Cfo	-	-	$0	$0

Fetched: 2026-06-16